Global X Cloud Computing ETF vs Pfizer Inc — how do they compare? Global X Cloud Computing ETF trades at $24.39, while Pfizer Inc trades at $24.56 (market cap $138.21B). The key difference: Pfizer Inc pays a 7.09% dividend while Global X Cloud Computing ETF pays none, and Global X Cloud Computing ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.
| CLOU | PFE | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $26.38 | $28.56 |
52-Week Low | $17.60 | $23.29 |
Market Cap | — | $138.21B |
Volume | — | 29,869,932 |
Enterprise Value | — | $188.87B |
Dividend Yield | — | 7.09% |
Signals from Pluang's Aura AI — not financial advice
CLOU trades at $24.11, up 1.49% with a bullish technical signal from moving averages. The ETF shows strong institutional interest in cloud computing exposure but faces mixed oscillators with RSI indicating overbought conditions. Recent news highlights both opportunity in underperforming tech sectors and concerns about cloud ETF performance trends.
The outlook balances cloud computing's growth potential against valuation concerns and sector volatility. Investment opportunity lies in AI-driven cloud adoption, while risks include competitive pressures and the ETF's historical underperformance compared to broader tech indices.
Pfizer (PFE) trades at $24.48, up 1.28% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $0.75 surpassing the $0.722 estimate. The company maintains solid profitability with a 73.51% gross margin and 11.83% net margin, while cash flow trends show positive net cash generation in 2025. News highlights focus on Pfizer's pipeline developments in obesity and oncology therapies.
The stock presents a value opportunity with a P/E of 18.51 below industry averages and a consensus price target of $28.78 implying 18% upside. However, risks include patent expirations, competitive pressures, and debt levels near 31% of assets. Analyst sentiment is mixed with 38% buy ratings versus 59% hold, suggesting cautious optimism amid pipeline execution uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →